Skip to main content

Table 2 Outcome

From: Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

early posttransplant period

 delayed allograft function (n, %)

14 (29.2)

 plasma creatinine at discharge (μmol/l)

141 [106–177]

 eGFRa at discharge (ml/min/1.73 m2)

43 [30–61]

 lowest thrombocyte count (109/L)

101 [79–132]

 time to lowest thrombocyte count (d)

2 [1–3]

long-term follow-up

 follow-up (yrs.)

3.3 [1.5–5.6]

 all-cause allograft loss (n, %)

14 (29.2)

 time to allograft loss (yrs.)

2.1 [0.4–2.9]

 death-censored allograft loss (n, %)

9 (18.8)

 plasma creatinine* (μmol/l)

124 [106–150]

 eGFRa * (ml/min/1.73 m2)

47 [39–65]

 BPARb (n, %)

12 (25)

  TCMR (n, %)

2 (4)

  ABMR (n, %)

10 (21)

 urinary tract infections/patient/year (n)

0.7 [0.4–2.4]

 viral infections (CMV, EBV)c (n, %)

7 (15)

 PVANd (n, %)

1 (2.1)

 prediabetes / PTDMe ** (n, %)

16 (38.1) / 13 (31.0)

  1. Data are given as median [interquartile range]
  2. aeGFR: estimated glomerular filtration rate (according to [16]); * of those with functioning graft; bBPAR: biopsy proven acute rejection, TCMR: T-cell mediated rejection, ABMR: antibody-mediated rejection; cCMV: cytomegalovirus, EBV: Epstein-Barr virus; dPVAN: polyomavirus-associated nephropathy; ePTDM: posttransplantation diabetes mellitus; ** of 42 patients without preexisting diabetes mellitus